Search >>
- Discovery
- Early Development
- Central Lab
-
Product Testing
- About Us
- Service Models
-
Services
-
BioPharma Product Testing Services
- Quality Control
- Cell Banking
- Process Validation
- Method Development
- Microbiology
- Clinical Trial Support
- Toxicology
- Biosafety Testing
- Custom and cGMP Radiolabeling
- Gene and Cell Therapy
- Category 5, Highly Potent/Toxic Materials Testing
- Regulatory and Quality Consulting Services
- PSS Insourcing Solutions
- Medical Device Testing
- Sterile Fill/Finish Manufacturing
- Human Factors Testing
-
BioPharma Product Testing Services
- Testing Services by Modality
- Locations
- Resources
-
News & Events
- Conferences & Fairs
- Webinars
- Announcements
-
Newsletters
-
Spring 2022
- Westward Ho!
- Viral Safety doubles laboratory footprint
- Sterility Testing Solutions for Every Project Need
- Whitford & Smith advance to new leadership roles in Portage and Columbia
- Major Stability expansion affords greater capacity and service opportunities
- Human Factors MD acquisition
- PSS Celebrates 20th Anniversary
- Pamala Adams
- Transition from R&D Cell Line Development to GMP Bank Manufacture
-
Fall 2022
- Online Ordering to LAWS
- Support next-generation biologics
- EBPT San Diego offers cell based bioassays
- Detection of mycobacterium species in qPCR
- Eurofins BioPharma Product Testing ENCO expands US capabilities footprint
- New Raw Materials Cell Based Services target cell viability and cell potency assays
- Understanding the when, why, and how - Eurofins Human Factors MD
- BioFire® assay
- Micro’s new Bruker MALDI speeds organism identification
- Scott Kingsley
- Spring 2023
-
Fall 2023
- The importance of a robust human factors engineering program
- Eurofins BPT grows Cell & Gene Therapy US Footprint
- Cell and Gene Therapies – When Speed Matters
- TOX and CTM Manufacturing at Eurofins BPT
- Honorable Mention in Sustainable Laboratory Awards
- Helium Usage Management
- Container Closure Integrity Testing needs
- Business in Ethics Award
- Eric Shaver
- Spring 2024
-
Spring 2022
- Contact Us
- Clinical Diagnostics
-
CDMO
-
Services
- Pre-Clinical - Safety & Efficacy Trials
- Small Molecules - API Development & Manufacturing
- Small Molecules - Solid State Research and Development
- Small Molecules - DP Development & Manufacturing
- Biologics - DS/DP Development & Manufacturing
- Cell & Gene
- Sterile Manufacturing / Fill & Finish
- Non-Sterile Manufacturing
- Clinical Trial Material, Packaging & Logistics
- Regulatory Services
- Quality by Design
- Cannabinoids - API/DP Development & Manufacturing
- Pediatrics
- Full clinical CRO and CDMO package
- SynPure LPA - Linear PolyAcrylamide
- Orphan Drugs
- ADME, CDMO & OPTIMED
- Locations
- Resources
- News & Events
- Contact Us
- 2023 Greetings | Eurofins CDMO
-
Services
-
Media
- Flyers - BioPharma Product Testing
- Flyers - Early Development
- Flyers - Genomic Services
-
Pharma Newsletters
- Eurofins BioPharma Services Newsletter 39 - December 2024
-
Eurofins BioPharma Services Newsletter 38 - August 2024
- Plasmid DNA manufacturing expands new service footprint at Eurofins CDMO
- 8 critical attributes your raw material testing partner must have
- Eurofins DiscoveryAI: Accelerating and empowering drug discovery with end-to-end computational services
- Environmental & Utility Monitoring Webinar offers clients key constraints & solutions
- Assessing usability to improve Medical Device efficacy
- Eurofins CDMO Alphora Inc. expands its Drug Product Analytical Laboratory
- MALDI-TOF creates unique proteomic fingerprint for microbial identification
-
Eurofins BioPharma Services Newsletter 37 - February 2024
- Extractables LC/MS Search Engine offers a novel database for E&L identification
- New FDA Guidance: Screening for Diethylene Glycol and Ethylene Glycol Contamination
- Platform methods validated at Eurofins BPT: the future for ATMP analytics
- Eurofins CDMO Alphora announces completion of a new pilot scale biologics development facility
- Eurofins’ new Clinical Trial Supplies makes the complex simple
- Eurofins Discovery accelerates Target Protein Degradation drug discovery
-
Eurofins BioPharma Services Newsletter 36 - October 2023
- Oxidative stress in cell culture: getting the most from your growth factors
- How effective is the cleaning process of my medical device?
- A comprehensive testing solution for mycoplasma comparable validation
- Eurofins Discovery presents obesityLITE Panel Fit-for-Purpose Solutions
- Eurofins BPT Les Ulis at the forefront of inhalation products testing
- Eurofins BioPharma Services expands its biological sample storage services with the Hamilton BiOS XL4, offering clients unparalleled safety and security
- Eurofins BioPharma Services Newsletter 35 - June 2023
- Eurofins BioPharma Services Newsletter 34 - February 2023
- Eurofins BioPharma Services Newsletter 33 - October 2022
-
Eurofins BioPharma Services Newsletter 32 - June 2022
- Eurofins Central Laboratory supports clinical trials in China’s regulatory landscape
- Eurofins BPT Italy develops Container Closure Integrity Testing for Biologic Drugs with Pressure Decay technique
- 20 years of bringing managed laboratory services to client sites and exponential global growth
- Eurofins BioPharma Product Testing Europe earns ISO 14001 certification
- Eurofins BPT Kyoto offers foreign matter analysis services for CGT products
- Eurofins Viracor expands
-
Eurofins BioPharma Services Newsletter 31 - February 2022
- Eurofins BPT Toronto expands psychedelics testing and certification services to support mental health therapies
- Eurofins CDMO helps solve the rising challenge of colon drug delivery for biologics
- Organoids: the next step in precision oncology
- The future of drug discovery
- Eurofins BPT Italy expands biologics testing capacity with new fully operational BSL2 facility
- Eurofins Central Laboratory solves PBMC processing challenges in global clinical trials
-
Eurofins BioPharma Services Newsletter 30 - October 2021
- Eurofins Viracor targets precision oncology with the launch of PanCancerIQ
- In Vitro potassium release assay for liposomal formulations of Amphotericin B – a requirement for Bio-IND applications
- EU MDR requires onsite Person Responsible for Regulatory Compliance
- Innovative particle size distribution and thermal analysis techniques are key to solving powder characterisation challenges
- EBPT Ireland expands footprint into high-throughput glycoprofiling of biologics with 2-AB labelling, offering development, qualification and validation services
-
Eurofins BioPharma Services Newsletter 29 - June 2021
- Eurofins Viracor BioPharma partners with Moderna, performing essential clinical trial testing for COVID-19 Vaccine
- Coumarin in cosmetics: Clarifying the safety controversy
- Eurofins utilises ultrasensitive methods in the battle against neurodegeneration
- Analytical Quality by Design: Eurofins BPT France delivers new level of expertise for methods development
- Eurofins Biomnis is helping psychiatrists to optimise the choice of antidepressants in the treatment of depression
-
Eurofins BioPharma Services Newsletter 28 - February 2021
- Eurofins Viracor BioPharma partners with Moderna, performing essential clinical trial testing for COVID-19 Vaccine
- Eurofins holds a wealth of cGMP experience testing RNA based drugs
- Eurofins Bioanalytical Services develops surrogate virus neutralising antibody detection assays against SARS-CoV-2
- Targeting pro-inflammatory cytokines for COVID-19 therapy: Qualified cell-based assays for accelerated drug discovery
- Eurofins launches new tests and massive capacity to detect and monitor new variants of SARS-CoV-2
- Testing disinfectants for virucidal efficacy, a daily job at Eurofins!
- Contacts
- << Return to BioPharma Services